entertainment -WSS

entertainment

author：explore 2025-10-02 19:38:29 - browse：8

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Does Medicare's free annual wellness visit do any good?

WSS

Study: Hearing aids may slow cognitive decline in those at risk

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Calls for Trump's election interference trial to be televised part of long debate

FDA seeking to stop procedures at two unregulated stem cell clinics

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Study: Hearing aids may slow cognitive decline in those at risk

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

As demand for Covid shots wanes, Moderna seeks its next success

Flagship, Pfizer team up in deal worth up to $7 billion

Psychedelics group wrestles with new pharma identity

A Theranos scientist

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Study: Hearing aids may slow cognitive decline in those at risk

New air purifier tech could be key to improving indoor air quality

'Cuddling' is just what the doctor ordered for a 200

Guidelines to prevent youth baseball injuries need more muscle

Pharma needs to include young adults in clinical research

entertainment

A strong 6.5

Parkland mass shooting to be reenacted for lawsuit

More hospitals are billing patients as online messages surge

ER docs worry over extreme heat as a 'mass casualty event'

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Medical mystery: When an infection after surgery isn’t what it seems

knowledge

knowledge

focus

Wikipedia